Case Name (Date)

Brown et al. v. ZMB Enterprises LLC
22-cv-54, S.D. Cal.
(Jan. 2022)


Product/Service

XanRelax and Addall


Allegations

Misleadingly labeling products as “dietary supplements” when they contain illegal ingredients and thus do not meet the definition of “dietary supplement” under federal law

Misleadingly using the name XanRelax to make consumers believe the product provides benefits similar to the prescription drug Xanax

Misleadingly using the name Addall to make consumers believe the product provides benefits similar to the prescription drug Adderall

Falsely marketing products as able to treat, cure, and prevent diseases, including depression, anxiety, and ADHD, and without FDA approval to do so


Status

Pending



The Latest

Filters

Fisher Investments

Ad Alert

Fisher Investments

Unearthing the fees that Fisher charges but doesn’t disclose in some of its TV ads.


Show More